Get 20% Off All Market Studies With Code ONLINE20 – Anticipate Tariff Impacts, Market Disruptors, and Long-Term Growth Trends
What Is the Expected Market Growth Rate for the Ovarian Cancer Drugs Market?
The ovarian cancer drugs market size has grown rapidly in recent years. It will grow from $5.15 billion in 2024 to $5.83 billion in 2025 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to rising incidences of ovarian cancer, a rise of new medications and therapies, an increase in government initiatives for ovarian cancer treatment and increased healthcare expenditure.
The ovarian cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $10.1 billion in 2029 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to increasing geriatric population and an increase in pharmaceutical R&D expenditure. Major trends in the forecast period include launching antibody-drug conjugates, partnerships and collaborations to improve revenues and product offerings, and focus on implanted drug factories for ovarian cancer.
Claim your free report sample now:
Which Major Growth Factors Are Shaping the Ovarian Cancer Drugs Market?
The rising incidence of ovarian cancer is driving the ovarian cancer drugs market. Furthermore, ovarian cancer is recorded to be the eighth most commonly occurring cancer in women and the 18th most commonly occurring cancer across the globe. For instance, in 2023, according to the Ovarian Cancer Statistics, published by the American Cancer Society, a US-based government organization, about 19,710 new cancer cases and 13,270 deaths were expected in the USA. Thus, the increasing incidence of ovarian cancer cases across the globe drives the growth of the ovarian cancer drugs market.
What Are the Emerging Segments in the Ovarian Cancer Drugs Market?
The ovarian cancer drugs market covered in this report is segmented –
1) By Tumor Type: Epithelial Ovarian Cancer, Germ Cell Ovarian Cancer, Stromal Cell Ovarian Cancer
2) By Drug Type: Alkylating Agents, Mitotic Inhibitors, VEGF/VEGFR inhibitors, PARP inhibitors, Other Drug Types
3) By Distribution Channel: Hospital Pharmacies, Drug Stores, Other Distribution Channels
Subsegments:
1) By Epithelial Ovarian Cancer: Serous Carcinoma, Endometrioid Carcinoma, Clear Cell Carcinoma, Mucinous Carcinoma
2) By Germ Cell Ovarian Cancer: Dysgerminoma, Yolk Sac Tumor, Teratoma, Embryonal Carcinoma
3) By Stromal Cell Ovarian Cancer: Granulosa Cell Tumor, Sertoli-Leydig Cell Tumor, Thecoma, Fibroma
What Are the Top Trends Expected to Shape the Ovarian Cancer Drugs Market by 2029?
Major companies operating in the ovarian cancer drug market are focusing on producing innovative solutions, such as breast and ovarian cancer treatment, to enhance therapeutic efficacy and improve patient outcomes. Breast and ovarian cancer treatment refers to a range of medical approaches designed to manage and combat breast and ovarian cancers, which are both distinct types of malignancies that can affect women. For instance, in June 2024, Shorla Oncology, an Ireland-based pharmaceutical company, received FDA approval for Tepylute, a new ready-to-dilute formulation of thiotepa for the treatment of breast and ovarian cancers. This liquid version simplifies administration by eliminating the need for complex reconstitution, ensuring consistent dosing accuracy. The recommended dosage ranges from 0.3 mg/kg to 0.4 mg/kg, administered intravenously every 1 to 4 weeks, with initial higher doses followed by maintenance adjustments based on blood counts.
Which Companies Hold the Largest Share in the Ovarian Cancer Drugs Market?
Major companies operating in the ovarian cancer drugs market include AstraZeneca plc, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Amgen Inc, Bristol-Myers Squibb Company, Clovis Oncology, Pfizer, Inc., Novartis AG, Pharma Mar SA, Vivesto, BDR Pharmaceutical, GLS Pharma, Eisai Co., Ltd., Denovo Biopharma, Jiangsu Hengrui Medicine, BeiGene, Innovent Biologics, Zai Lab, EUSA Pharma, Recordati , NEUCA, Farmacol, Polska Grupa Farmaceutyczna, Polpharma, TZMO, Msd Sanofi, Gilead Sciences, Johnson & Johnson, Merck & Co, AbbVie Inc, Aa Pharma In, Aaladin Superior Cleaning Systems Ltd, Accel Pharma Inc, EMS Pharma, Eurofarma, Neo Química, Mantecorp Farmasa, Abbott Laboratories Bayer, Laboratorio Elea Phoenix, Laboratorios Ac Farma, Teva, Monte Verde, Gador, Spimaco, Tabuk Pharmaceuticals, Jamjoom Pharma, Abcon International L.L.C., Adcan Pharma, Regal Pharmaceuticals Limited
Get the full ovarian cancer drugs market report here:
Which Regions Are Driving the Most Demand in the Ovarian Cancer Drugs Market?
North America was the largest region in the ovarian cancer drugs market in 2024. Middle East is expected to be the fastest-growing region in the global ovarian cancer drugs market share during the forecast period. The regions covered in the ovarian cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment